Gene Therapy Treats Rare Childhood Blindness
Gene Therapy Offers Hope for Children with Severe Eye Condition
Table of Contents
By NewsDirectory3
An experimental trial of gene therapy has brought hope to four toddlers born with one of the most severe forms of childhood blindness. Doctors at Moorfields Eye Hospital in London have reported “life-changing improvements” in the sight of these children, offering a beacon of hope for families affected by similar conditions.
The rare genetic condition, Leber Congenital Amaurosis (LCA), causes rapid deterioration of vision from birth. Before the therapy, the children were legally blind and could only distinguish between dark and light. After the infusion, all parents reported significant improvements, with some children now able to begin drawing and writing.
Further work is being done to confirm the early study, which appears in the Lancet medical journal. The trial builds on the success of gene therapy for another form of genetic blindness, which has been available on the NHS since 2020. This new work involves injecting healthy copies of a defective gene into the back of a child’s eye very early in life, treating a severe form of the condition.
Jace, from Connecticut, had the gene therapy in London when he was just two years old. His parents noticed something wasn’t right about his eyesight when he was around eight weeks old. “Around eight weeks old when babies should start looking at you and smiling, Jace wasn’t doing that yet,” says his mum DJ. “She knew instinctively there was an issue and began to search for the reason, which took 10 months.”
After several visits to doctors and many tests, the family were told Jace had the ultra-rare condition caused by a mutation to a gene called AIPL1, with no established treatment. “It was a shock,” Jace’s dad Brendan says of his first child. “You never think it’s going to happen to you, of course, but there was a lot of comfort and relief to finally find out… because it gave us a way to move forward.”
The family was lucky to hear about an experimental trial being carried out in London just by chance when they were at a conference about the eye condition. Jace’s surgery was quick and “pretty easy,” his mum says. He had four tiny scars in his eye where healthy copies of the gene were injected into the retina at the back of the eye through keyhole surgery. These copies are contained inside a harmless virus, which goes through the retinal cells and replaces the defective gene. The healthy, working genes then kick-start a process which helps the cells at the back of the eye work better and survive longer.
In the first month following treatment, Brendan noticed Jace squint for the first time on seeing bright sunshine streaming through the windows of their house. “His son’s progress has been ‘pretty amazing,’ he says. ‘Pre-surgery, we could have held up an object near his face and he wouldn’t be able to track it at all. Now he’s picking things off the floor, he’s hauling out toys, doing things driven by his sight that he wouldn’t have done before.'”
Prof James Bainbridge, a retinal surgeon at Moorfields Eye Hospital, who helped lead the trial, said giving children the chance of sight improvement this early on could make a big difference to their development and ability to interact with people. “Sight impairment in young children has a devastating effect on their development. Treatment in infancy with this new genetic medicine can transform the lives of those most severely affected,” he said. The four children, from the United States, Turkey, and Tunisia, were all born with an aggressive form of Leber Congenital Amaurosis, where a genetic fault means the cells at the back of their eyes – that normally help distinguish light and color – malfunction and rapidly die out.
Scientists at University College London developed the innovative procedure, which involves infusing healthy copies of the gene into the back of the eye. Unlike traditional scientific trials, families were offered this experimental therapy under a special licence designed for compassionate use, when there are no other options readily available. Children had one eye treated each – a measure taken in case the treatment had any adverse effects. They were aged between one and three when they had the procedure and their vision was then checked at intervals over the next four years, in a variety of ways – including moving down corridors and identifying doors. Given their age, some children found the more formal eye tests challenging.
No Other Options
For families like Jace’s, the lack of established treatments for LCA made the experimental gene therapy a last resort. “It was a shock,” Brendan recalls. “You never think it’s going to happen to you, but there was a lot of comfort and relief to finally find out… because it gave us a way to move forward.”
Jace’s family was lucky to hear about the trial just by chance when they were at a conference about the eye condition. The surgery was quick and “pretty easy,” his mum says. Jace had four tiny scars in his eye where healthy copies of the gene were injected into the retina at the back of the eye through keyhole surgery. These copies are contained inside a harmless virus, which goes through the retinal cells and replaces the defective gene. The healthy, working genes then kick-start a process which helps the cells at the back of the eye work better and survive longer.
In the first month following treatment, Brendan noticed Jace squint for the first time on seeing bright sunshine streaming through the windows of their house. “His son’s progress has been ‘pretty amazing,’ he says. ‘Pre-surgery, we could have held up an object near his face and he wouldn’t be able to track it at all. Now he’s picking things off the floor, he’s hauling out toys, doing things driven by his sight that he wouldn’t have done before.'”
This may not be the last treatment he needs in his life, his parents say, but the improvements so far are helping him to know the world better. “It’s really hard to undersell the impact of having a little bit of vision,” Brendan says.
‘Hugely Impressive’
According to Moorfields’ doctors, the results of the tests they completed, alongside the parents’ reports of their improvements, give “compelling evidence” that all four benefited from the treatment and were seeing more than would be expected with the normal course of the disease. Vision in their untreated eyes, meanwhile, deteriorated, as expected.
Consultant eye surgeon, Prof Michel Michaelides, at the UCL Institute of Ophthalmology, added: “The outcomes for these children are hugely impressive and show the power of gene therapy to change lives.” The team plans to monitor the children to see how long-lasting the results are. The results so far give them hope that intervening early in other childhood genetic eye conditions could offer the “greatest benefit” and ultimately transform children’s lives.
While the results are promising, it’s important to note that gene therapy is still a relatively new field, and more research is needed to fully understand its long-term effects and potential risks. However, the success of this trial offers a glimmer of hope for families affected by LCA and other genetic eye conditions.
For families in the U.S., the availability of such treatments may still be limited, but the progress made in the UK highlights the potential for similar advancements in the future. As gene therapy continues to evolve, it could offer new hope for children and families affected by genetic diseases, providing a path to improved quality of life and a brighter future.
Gene Therapy for Severe Eye Conditions: A Beacon of Hope
Overview
gene therapy has emerged as a promising treatment for children with severe eye conditions, notably Leber Congenital Amaurosis (LCA). This innovative approach has shown “life-changing improvements” in newly treated toddlers, as reported by doctors at Moorfields Eye Hospital in London. Here, we delve into the specifics of this therapy, its impact on patients, and its potential implications for future medical advancements.
What is Leber Congenital Amaurosis (LCA)?
Definition and Impact:
LCA is a severe genetic disorder that leads to rapid deterioration of vision from birth. Children with this condition are typically legally blind and are only able to distinguish between light and dark.
Prevalence:
LCA is a rare condition, with approximately 30 genes implicated in its progress.
Current Treatments:
Before gene therapy, treatment options were limited, leading to progressively worsening vision for affected children. [[1]]
how Does Gene Therapy Work for LCA?
Mechanism:
Gene therapy for LCA involves injecting healthy copies of a defective gene into the retina. This process uses a harmless virus to replace the faulty gene, helping retinal cells function better and survive longer. This therapy was specifically developed by scientists at University College London.
Procedure:
The treatment involves keyhole surgery to administer the gene directly into the eye. Typically, only one eye is treated initially to monitor for potential adverse effects.
Patient outcomes and Improvements
Initial Results:
Parents of treated children, such as Jace, a young participant, have reported significant improvements. Where once their children couldn’t track objects, they now engage in sight-driven activities like drawing and identifying objects.
Patient Testimonies:
Jace’s parents noticed remarkable changes in his behaviour and abilities shortly after the procedure. His ability to interact with his environment is markedly enhanced post-treatment.
Clinical Findings:
Doctors at Moorfields Eye Hospital have observed “compelling evidence” that the treated children showed more progress than would have been expected without intervention. Vision in their untreated eyes deteriorated as was to be expected, highlighting the effectiveness of the therapy.
Long-Term Monitoring:
Researchers plan to continue monitoring these children to evaluate the long-term effectiveness and durability of the treatment. [[2]]
Prospects and Challenges
Potential and Limitations:
The success of gene therapy for LCA is promising, yet gene therapy is still in its infancy.Further research will be needed to fully understand its risks and long-term effects.
Availability:
While significant progress is noted in the UK, the availability of such cutting-edge treatments remains limited in other regions, like the US. However, ongoing successes indicate a hopeful path forward.
expert Opinions
Support from Specialists:
Experts, including Prof Michel Michaelides from the UCL Institute of Ophthalmology, acknowledge the “hugely extraordinary” outcomes of the therapy. Such success stories encourage further advancements in genetic medicine for childhood conditions.
Conclusion
Gene therapy offers a groundbreaking approach to treating severe eye conditions like LCA, providing hope for affected children and their families. As research progresses, ther is significant potential for these therapies to transform lives, paving the way toward future medical breakthroughs.
By integrating expert opinions, clinical findings, and relatable patient stories, this Q&A-style article provides a thorough understanding of gene therapy’s current state and future prospects in treating severe eye conditions.